Claims

1. (currently amended) A compound having the formula:



(I)

wherein R^1, R^2, R^3 and R^4 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, OR^8, NO_2, CN and halogen;

wherein R^8 is a member selected from H and substituted or unsubstituted alkyl;

R^5 and $R^{5'}$ are members independently selected from ~~H,~~ substituted alkyl, substituted or unsubstituted alkenyl or alkynyl, ~~alkyl~~, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, CN, SR^9 and $C(O)R^9$;

wherein R^9 is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, $NR^{10}R^{11}$ and OR^{11};

wherein R^{10} is a member selected from H, substituted or unsubstituted alkyl, and OR^{12};

wherein R^{12} is a member selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl;

R^{11} is a member selected from H, $C(O)R^{13}$, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocycloalkyl, and wherein R^{10} and R^{11}, together with the nitrogen to which they are bound, are optionally joined to form a substituted or unsubstituted heterocycloalkyl ring system having from 3 to 7 members;

wherein R^{13} is a member selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and $NR^{14}R^{15}$;

wherein R^{14} and R^{15} are members independently selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl;

R^6 and $R^{6'}$ are members independently selected from H, substituted or unsubstituted alkyl, and $C(O)R^{16}$;

wherein R^{16} is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, $NR^{17}R^{18}$ and OR^{17};

wherein R^{17} and R^{18} are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and substituted or unsubstituted aryl; and

R^7 is a member selected from H, substituted or unsubstituted alkyl, and substituted or unsubstituted heteroalkyl.

2. (previously presented) The compound according to claim 1, wherein at least one of R^5 and $R^{5'}$ is a member selected from substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted furanyl, substituted or unsubstituted benzofuranyl, substituted or unsubstituted quinolinyl, and substituted or unsubstituted thienyl.

3. (previously presented) The compound according to claim 1, wherein at least one of R^{10} and R^{11} is substituted or unsubstituted C_1-C_6 alkyl.

4. (previously presented) The compound according to claim 1, wherein at least one of R^6 and $R^{6'}$ is a member selected from substituted or unsubstituted C_1-C_6 alkyl.

5. (previously presented) The compound according to claim 1, having the formula:



6. (previously presented) The compound according to claim 5, having the formula:



7. (previously presented) The compound according to claim 6, wherein R^{11} is substituted or unsubstituted C_1-C_4 alkyl.

8. (previously presented) The compound according to claim 5, wherein at least one of R^5 and $R^{5'}$ is a member selected from substituted or unsubstituted:



9. (previously presented) The compound according to claim 5, wherein R^6 and $R^{6'}$ are independently selected from substituted or unsubstituted methyl and substituted or unsubstituted ethyl.

10. (previously presented) A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. (previously presented) A method of inhibiting HIV in a cell, said method comprising contacting said cell with an amount of a compound according to claim 1 sufficient to inhibit said HIV.

12. (previously presented) A method of inhibiting reverse transcriptase in a cell, said method comprising contacting said cell with an amount of a compound according to claim 1 sufficient to inhibit said reverse transcriptase.

13. (previously presented) The method according to claim 11, wherein said cell is in a human.

14. (previously presented) The method according to claim 12, wherein said cell is in a human.

15. (previously presented) A method of treating HIV infection in a human subject comprising administering to said subject an amount of a compound according to claim 1, sufficient to treat said HIV infection.

16. (canceled)

17. (previously presented) The method according to claim 15, wherein said HIV is a drug resistant mutant.

18. (new) The compound of claim 1, wherein said compound is selected from the group consisting of



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,



and


19. (new) A pharmaceutical formulation comprising a compound according to claim 18 and a pharmaceutically acceptable carrier.

20. (new) A method of inhibiting HIV in a cell, said method comprising contacting said cell with an amount of a compound according to claim 18 sufficient to inhibit said HIV.

21. (new) A method of inhibiting reverse transcriptase in a cell, said method comprising contacting said cell with an amount of a compound according to claim 18 sufficient to inhibit said reverse transcriptase.

22. (new) The method according to claim 20, wherein said cell is in a human.

23. (new) The method according to claim 21, wherein said cell is in a human.

24. (new) A method of treating HIV infection in a human subject comprising administering to said subject an amount of a compound according to claim 18, sufficient to treat said HIV infection.

25. (new) The method according to claim 24, wherein said HIV is a drug resistant mutant.